Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Asco Exhibits
The Asco website has been updated and NWBO is listed as an exhibitor. Exhibits were due to open today, but it looks like you need to login to the site.
https://asco21.onlineeventpro.freeman.com/
Autolomous AutoloMATE platform
Advent has long been listed as a client of Autolomous, but this recent press release is the first time I’ve seen them refer explicitly to a dc product.
I hope there is one, but my post was regarding the release of the titles. It looks like they may have explicitly added the words “all” and “including LBAs” to the schedule for April 28 - I didn’t get a screenshot of the original page put the post I responded to posted the schedule without these words.
Anyway, what will be will be. I’ve got my fingers and toes crossed for good news.
Maybe this has been mentioned already, but the timetable for Asco now says this for April 28th
All abstract titles released, including LBAs.
I think the bold is new? Also, there seems to be a link on the bottom of the following page to the publish only abstracts (which I thought were scheduled for May 19).
https://conferences.asco.org/am/program
Isn’t the ASM normally at the weekend? Tuesday at 4:30pm, 24 hours before ASCO abstracts are released is curious.
Interesting observation, also with the “provisional” watermark on the charts.
Autolomous grant
Last year it was reported (link below) that Autolomous were going to announce their “U.S. collaborator later this month”
I’m not sure this happened. A bit like NWBO’s TLD never came.
Today I noticed that Autolomous have been awarded a UK government grant.
Probably 100% unconnected - but I’m sure someone on here will enjoy linking the grant to NWBO somehow
For what it’s worth, I have a feeling there’s a really strong connection between NWBO and Autolomous.
https://www.genengnews.com/topics/bioprocessing/boosting-capabilities-in-gene-and-cell-therapy-bioprocessing/
https://www.thegazette.co.uk/company/11810723/filing-history/MzI5NjQxMTM0M2FkaXF6a2N4
Flaskworks
https://www.sec.gov/Archives/edgar/data/1072379/000110465921044832/nwbo-20201231xex10d83.htm
I may have missed discussion about this, or it may just not be interesting, but this document filed with the 10-k reassured me a lot for two reasons:
1. The 10-K states that one of the Flaskworks milestones was met. A number of the milestones as listed in this document are related to getting Flaskworks setup for use with DCVax specifically and there’s also a specific mention of Advent in one of the milestones.
2. It looks like Northeastern University had/has the option of taking some of the amount they were due in shares “special expenses”. It looks like this decision is purely theirs and not NWBO’s and it also looks like they were the only ones with “special expenses” Now, they might not have exercised this right, but to have it specifically called out in the agreement is interesting IMHO.
I’m not a lawyer so i could be misinterpreting things, but IMHO these items are interesting.
Current list of ASCO 21 exhibitors:
https://events.jspargo.com/ASCO21/CUSTOM/OnlineExhibitorList.pdf
No sign of NWBO.....yet
Thanks Ex.
Flaskworks is one of the reasons I’m optimistic about NWBO. Knowing you’re less optimistic, how does this fit in with what you think is going on? Seems odd to spend money on getting their system integrated with DCvax specifically.
Any idea what milestone was met? Not sure what percentage 1.5 million is. Also haven’t read the whole agreements so may be missing some context.
10-K
Exhibit 10.83
Has anyone read this exhibit to the 10-k? It’s the unit purchase agreement for Flaskworks and details the vesting criteria - the 10k states that a significant milestone was reached on 12/1 and 1.5 million shares were issued.
The criteria are detailed so I’ll let someone else try and explain.
Still blinded?
I haven’t been on the board for a few days so apologies if this has already been posted:
https://www.sciencedirect.com/science/article/pii/S1042368021000036?via%3Dihub
Also, I came across another journal but a lot of it seems to be in Russian:
https://scholar.googleusercontent.com/scholar?q=cache:8Ac0ZX5JVeAJ:scholar.google.com/+Dcvax&hl=en&as_sdt=0,24&as_ylo=2021
Brief DCVax in this paper published today. Don’t think there’s anything new?
https://res.mdpi.com/d_attachment/jcm/jcm-10-01367/article_deploy/jcm-10-01367.pdf
Nice find. Interesting that one of the roles is a 9 month contract and includes the following in the job description:
Leading the set-up of a comprehensive materials onboarding process
I wonder why they would need a new process for receiving materials, within the next 9 months?
https://www.thetimes.co.uk/article/cancer-patients-face-2-000-covid-test-bill-for-treatment-abroad-cpl5stfhq
Looks like DCVax is mentioned in this article but I don’t have a subscription so not sure what the context is.
Aracaris Limited - NWBOs UK subsidiary - filed their 2019 accounts yesterday. On a first pass, nothing seems very exciting to me (especially given these are somewhat stale), a small increase in tangible assets and a slightly larger increase in amounts due to related parties.
https://find-and-update.company-information.service.gov.uk/company/09103355/filing-history
When is the 10-K due? I know there were some changes to the filing status discussed here last quarter, but I thought accelerated filers were due yesterday?
With new auditors I would have thought they would be keen to get things done on time. On the flip side, it seems like a good reason why they might actually be late
Flaskworks patent - new document published last month
https://patentimages.storage.googleapis.com/52/a7/a4/8579aba44d9f16/US20210047600A1.pdf
Not sure if this has already been posted, so apologies in advance. Further, I’m pretty clueless with patents so not sure if this is even significant.
I always read NWBO’s PRs multiple times - LP and LG are lawyers and I think they’re very careful with what they say.
After my initial read, and all IMHO, I was a little disappointed. I thought there was nothing really new. Plus they mention other third parties utilizing the excess production capacity which made me think of some of the comments on here about shareholders basically funding another CDMO.
However, on subsequent reads I’m now more bullish. My interpretation is that the two suites are designed primarily (maybe solely?) for NWBO. Further, the PR discusses recruitment specific to “ manufacturing, quality control and other operations of the first two production suites”. It sounds to me as though they’re fully staffed to start up the two initial suites for NWBO and from LinkedIn it appears that a recent PhD recruit is experienced in immuno-oncology. If I was recruiting and was unsure of approval, I’m not sure I’d get everyone signed up so early.
Finally, they talk about TLD in the “coming months”. ASCO is also in the coming months....
My one question is why release this PR now? It doesn’t seem like we’ve hit an explicit milestone with Sawston and they could have waited until they have MHRA sign off / approval.
All this is IMHO and nothing will ever surprise me as a owner of NWBO stock.
I’m generally an impatient person but I’ve just had my 4th anniversary as a NWBO shareholder. I realize this makes me a relative newcomer, but for me this seems like forever.
Just for fun as we approach another ASCO (which always seems to get people excited - and then disappointed), what’s everyone’s best guess as to when we get any news that moves the share price by plus or minus 50%?
I’m just hoping we don’t get an abstract title at ASCO that then gets pulled.
GHK Companies - https://ghkco.com/
Anyone know anything about these guys? They list NWBO as an investment and their description of NWBO seems recent.
Question about ethics.... or maybe law...
Assuming, hypothetically, that the company is now unblinded and knows the efficacy of DC Vax, would they have to stop the compassionate use program if they knew that the primary endpoint had not been met?
Lykiri, thanks for the response.
Also, I wasn’t able to watch the session that Bosch moderated earlier this week (and I can’t find a recording yet). You seemed to be quite positive about it - was there anything specific to NWBO mentioned?
Appreciate all your awesome insight and research!
Lykiri,
Do you think maybe we can assume Sawston is fully up and running? In addition to your post today, I noticed on LinkedIn that the consultant they were using (with experience in inspections) is no longer with Advent as of sometime in January. You originally posted about this individual in November:
I’ve been off the board for a while so apologies if this has been discussed.
The 10-K included the following:
Advent’s 2019 financial statements were filed yesterday:
https://find-and-update.company-information.service.gov.uk/company/08717711/filing-history
If there has been a further warrant suspension, do they have to 8k this before the previous suspension lifts - I.e. pre trading tomorrow?
Apologies if this has been discussed already.
Doc, don’t get me wrong, I’m very long. Not as invested as many on here but I have 100k+ shares that I’ve accumulated over the past 4 years at an average price around 20 cents. That said, it was the notion that this is nearly 100% derisked that made me giggle. Markets are never perfect, but this would be trading much higher if this was the case. All IMHO of course.
Completely agree.
LC, I’m long but my reaction was similar. Not sure how anyone can think that this is anywhere near 100% de-risked.
I want the company to succeed and I’m hopeful. But delay upon delay and an IR contact that, in my experience responds selectively to messages doesn’t say de-risked to me. Trial results that we were expecting months ago that are not ready yet - doesn’t scream de-risked in my opinion.
Seriously, I want the company to succeed, I really do. But this made me giggle.
IMHO, we get a brief PR with results anytime between now and Friday 12/11. Reasons for this being:
1. Warrant extension - I’ve got to believe that the company allowed for some additional delays when determining the date to suspend these warrants and they think the SP will be sufficiently higher by the end of the current suspension.
2. ESMO immuno-oncology conference - the timing of this conference 12/9-12/12 seems to coincide well with the suspension of the warrants. Or maybe just a coincidence. From looking at the current schedule, it doesn’t look like the company or LL are currently scheduled to speak, but it would seem to be a good venue to drop some news.
3. Financing - it’s been a while since the company disclosed any financings. I would guess costs are quite high right now with the statisticians plus extra salaries for Flaskworks. I would hope we get news before a financing.
4. 10-Q - I’m likely being naive, but I’m connecting the delay with the 10-Q with TLD, not sure how it’s connected but I personally think it is. Surely we see the 10-Q soon.....
Of course, this is all IMHO and is probably all wrong. I truly wish the company would provide more updates and I personally don’t care about catching shorts as a lot here do. Long term shareholder value is more important to me than a short lived short squeeze.
I should have emphasized my sarcasm a little better. I just thought it was an amusing trade name to be registered in the first place. I can’t imagine a situation where it would ever be used.
I haven’t been through every page, but it doesn’t look like they were listed previously on the pages I looked at.
I wonder where OTC pulls this information from. Per hmuney, it seems like he was there, went away, came back.
This is the site I use to look at old pages:
https://web.archive.org/
This is old news - 18 years old in fact - but I’m very sad the company let this trade name expire:
https://tsdr.uspto.gov/#caseNumber=76325493&caseSearchType=US_APPLICATION&caseType=SERIAL_NO&searchType=statusSearch
I think he’s been on there for a few years? The link below is an archived page from 2017:
https://web.archive.org/web/20170729033528/https://www.otcmarkets.com/stock/NWBO/profile
Lykiri,
Very interesting, thank you.
They recently appointed a US based director too https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159238850
Do you think there could be any ownership/financial links between LP and Autolomous?
The reasons they stated for the delay were prefaced by the two words “such as” so not necessarily a definitive list of reasons.
My understanding is that the 10Q may cover things that occurred after Q3 if they would have a material effect on the financial statements. NWBO have disclosed such events in the past - for example financings that occurred after the balance sheet date.
What I found to be interesting was the comment regarding the accounting treatment of option awards. What would affect the accounting treatment of option awards? Just speculating, but accelerated vesting maybe? On the other hand, maybe it’s as benign as new awards were made with different performance conditions that are accounted for differently.
Hopefully we won’t have to speculate too much longer....
Not sure how I add a picture here, but if you click on the following link (I’m on an iPhone and it loads the mobile website, not sure about the desktop version) and then click on the company’s name.
https://eventscribe.net/2020/SNO/searchGlobal.asp?mode=exhibitors&SearchQuery=northwest